Cancer immunoprevention.

@article{Finn2016CancerI,
  title={Cancer immunoprevention.},
  author={Olivera Olja J Finn and Pamela L. Beatty},
  journal={Current opinion in immunology},
  year={2016},
  volume={39},
  pages={
          52-8
        }
}
Cancer immunotherapy is now a reality. The results are phenomenal but the cost is outrageous. Even if the cost eventually comes down and immunotherapy becomes more broadly available, using the knowledge derived from immunotherapy to apply to immunoprevention would be a good strategy. The most likely approach to cancer immunoprevention is cancer vaccines. To date, cancer vaccines have been tested mostly in the setting of advanced disease. Numerous immunosuppressive mechanisms have been… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells.

  • Journal of the National Cancer Institute
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

CD4 + T cells promote renal cell carcinoma proliferation via modulating YBX1.

  • Experimental cell research
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Cancer Immunotherapy, Part 3: Challenges and Future Trends.

  • P & T : a peer-reviewed journal for formulary management
  • 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

MUC 1 vaccine for individuals with advanced adenoma of the colon : a cancer Current Opinion in

T Kimura, McKolanis, +5 authors OJ Finn
  • Immunology
  • 2016